Omnichannel diagnostics platform Redcliffe Lifetech (Redcliffe), has raised $61 million in its Series B round led by LeapFrog Investments, with participation from Healthquad, Schroders, LC Nueva, Growth Spark Ventures and existing investors Chiratae Ventures and Alkemi Venture Partners.
Last year, the company had raised $10 million in its Series A round.
The investment will be used to expand Redcliffe’s geographic reach in India, and to scale Redcliffe’s platform and increase its product offerings to radiology, disease data profiling and lifestyle management.
Founded in 2018, Redcliffe delivers diagnostics services in its network of 22 labs across 14 cities, several of which it says are NABL-accredited.
Its omni-channel infrastructure combines online channels with a fleet of 400 phlebotomists operating in over 100 cities with home sample collection and an offline network of 500 collection centres. The company 3,500 different pathology and specialised tests including genetics at prices it says are around 25-60% less than traditional competitors.
